“Building a business is very difficult. It requires an unusual belief to persist in making original medicines. Although Bao Pharmaceuticals is young, it is now ready to strive to develop into a world-class biomedical company.” said Liu Yanjun, Chairman of Bao Pharmaceuticals, 

who led a team to Luodian Industrial Park to set up Bao Pharmaceuticals in December 2019. In March 2020, North Shanghai Biopharmaceutical Industrial Park with Luodian Industrial Park as its core area was officially awarded as one of the five municipal characteristic biomedical industrial parks. This has brought development opportunities to Bao Pharmaceuticals and facilitated the transformation and development of Luodian Town.

According to Liu Yanjun, the relocation of Bao Pharmaceuticals to Luodian Town is a mutually beneficial move that capitalizes on the favorable environment for innovative enterprises and supports the team’s efforts to advance innovative drug development.

Currently, Bao Pharmaceuticals is focused on two primary research and development areas, centered around “subcutaneous drug delivery technology that utilizes recombinant human hyaluronidase” and “pharmaceutical devices essential for assisted reproduction.” The company has established three core technology platforms, including the Pharmaceutical Enzyme Engineering Technology Center, Glycoprotein Pharmaceutical Engineering Technology Center, and Antibody Targeted Enzyme Engineering Technology Center. These platforms are dedicated to providing innovative solutions that meet clinical demands.

The R&D of new drugs is a long and lonely road, and the road ahead is often unknown. Liu Yanjun looks at drug R&D with the difference between one person and a group of people walking at night. “When walking at night, a group of people feels more confident and secure than an individual, who may be afraid of getting lost. However, the R&D OF Chinese biomedical companies are similar. If we want to do our own innovative R&D, we must believe that we are going right, which needs professionalism and concentration.”

As a veteran in the field of biomedicine, he has directed the R&D of ten bioengineering drugs and a class of new drugs, but his pace of innovation has never stopped. In less than three years, with the joint efforts of the team, Bao Pharmaceuticals has applied for 74 invention patents, including 8 authorized invention patents and 10 PCT international patents; Dozens of drug pipelines are under research, among which KJ017, SJ02 and other products have completed clinical research.

On the day before IgG degrading enzyme was approved for clinical use, Bao Pharmaceuticals, overcoming all difficulties, completed the B round of financing of over 100 million US dollars under the current elevated capital market pressure.

A group of innovative enterprises, represented by Bao Pharmaceuticals Co., Ltd., insist on continuously investing in R&D to realize the innovation value of enterprises while seeking further development under the favorable policies offered by the local government.

Liu Yanjun said that city-level support policies for drug development often require completion of clinical trials before funds can be allocated, resulting in a lengthy application period. After investigating the needs of enterprises, the main leaders of the CPC Baoshan District Committee and Baoshan District People’s Government launched the second edition of Biomedical Special Policy, which serves as a tangible policy dividend.

Baoshan District Biomedical Special Policy Edition 2.0 refers to Several Policies for Accelerating the High-quality Development of Biomedicine and Life and Health Industry revised and launched in Baoshan District. Since 2022, Baoshan District has listened carefully to the opinions of enterprises, repeatedly demonstrated and adjusted the Special Policy Edition 2.0 under the leadership of district leaders, aiming at giving the most favorable policy support to biomedical enterprises in the whole life cycle.

Luodian Town is a signature of North Shanghai. Great changes are taking place in this old town with a history of more than 600 years. The leading enterprises dealing with biological products, medical devices, original new drugs in the biomedical industry are gradually settling in North Shanghai Biomedical Industrial Park, thus forming an industrial ecological circle integrating “R&D, production and service”.